Courses › Nationality and niche combinations
Selling into Europe as a finished-dose generic company from the United States
Ensure your European market entry avoids costly regulatory delays.
The moment it goes wrong
A rejected marketing authorization application for your generic drug means months of lost revenue. Your team spent resources on a product that cannot be sold, delaying your entire European strategy. This directly impacts your quarterly targets and investor confidence.
What changes after this course
Your team will confidently discuss European market entry regulations and prepare correct submission documents. They will understand the pathways for finished-dose generics. You will have a verifiable training record for your entire commercial and regulatory staff.
How long it takes, by who is listening
Nobody spends a day in a classroom. Every module exists in three lengths; a person takes the length their role needs, and every length ends with the same recorded questionnaire, so the training record is complete either way.
| Who takes this course | Length | Total time |
|---|---|---|
| Owner, CEO and board | Briefing | 2 h |
| Business development and export sales | Briefing | 2 h |
| Regulatory affairs | Standard | 5 h |
| Quality assurance and Qualified Person | Standard | 5 h |
What is in the course, module by module
12 modules. Under each title are the three things the listener can do afterwards; the audio itself runs 10 to 50 minutes depending on the length chosen. Each module ends with a multiple-choice questionnaire whose result is recorded per person for your auditor. Your human-resources or quality manager decides what counts as passed and when a level is retaken.
1Understand the European Medicines Regulatory Landscape
- The European Medicines Agency (EMA) oversees the Centralized Procedure for specific drug types.
- National competent authorities manage decentralized and mutual recognition procedures for most generics.
- Assuming one unified European regulatory body exists for all applications is a common mistake that costs time.
2Choose the Correct Marketing Authorization Procedure
- Decide between the Centralized, Decentralized, and Mutual Recognition procedures based on product scope.
- The Mutual Recognition Procedure (MRP) requires a prior national authorization in a reference member state.
- Misselecting a procedure can lead to application rejection and delays, incurring significant costs.
3Prepare Your Quality Module (Module 3) Correctly
- Module 3 of the Common Technical Document (CTD) details the quality of the active substance and finished product.
- The European Pharmacopoeia provides official standards for substances used in medicines.
- Incomplete stability data in Module 3 causes major deficiencies and prolongs approval timelines.
4Compile the Non-Clinical and Clinical Overviews for Generics
- Module 2.4 (non-clinical overview) and 2.5 (clinical overview) summarize key studies for generic products.
- Bioequivalence studies are crucial for demonstrating interchangeability with the reference product.
- Failing to show bioequivalence can lead to a refusal to grant marketing authorization.
5Master the Generic Marketing Authorization Application
- The abridged application pathway is used for generic medicinal products based on a reference product.
- European Directive 2001/83/EC outlines the legal framework for marketing authorizations.
- Incorrectly referencing the innovator product can invalidate your entire generic application.
6Manage Good Manufacturing Practice (GMP) Compliance
- All manufacturing sites must comply with EU Good Manufacturing Practice (GMP) requirements.
- An EU GMP certificate from a recognized authority is mandatory for importation of finished-dose generics.
- Non-compliance with GMP can result in product batch rejection at the border, a costly error.
7Understand Importation and Batch Release Requirements
- A Qualified Person (QP) in the European Union must certify each imported batch before release.
- Article 51 of Directive 2001/83/EC governs the role and responsibilities of the Qualified Person.
- Delays in QP release due to missing documentation can halt product supply to the market.
8Address European Pharmacovigilance Obligations
- A comprehensive pharmacovigilance system is required to monitor drug safety post-authorization.
- The Marketing Authorization Holder must maintain a Pharmacovigilance System Master File (PSMF).
- Non-adherence to pharmacovigilance rules can lead to product withdrawal and significant fines.
9Prepare for Post-Authorization Changes and Variations
- Any change to the approved marketing authorization requires a variation application to regulators.
- Commission Regulation (EC) No 1234/2008 defines the types and procedures for variations.
- Implementing unapproved changes can result in regulatory penalties and product recalls.
10Price and Reimburse Your Generic Product in Europe
- Pricing and reimbursement decisions are typically made at the national level, not EU-wide.
- Companies must understand national health technology assessment (HTA) requirements.
- Misjudging local pricing strategies can lead to market access failure, wasting investment.
11Develop Your European Commercial Strategy
- Understand the diverse market access pathways and tendering systems across different EU countries.
- Identify key stakeholders, including national health services, pharmacists, and prescribers.
- Entering a market without local insights can result in low market penetration and lost sales.
12Prepare for Regulatory Inspections and Audits
- European regulatory authorities conduct routine and for-cause inspections of manufacturing sites.
- Companies must demonstrate compliance with Good Clinical Practice and Good Pharmacovigilance Practice.
- Failing an inspection can lead to product suspension or revocation of marketing authorization.
Price for this title
One licence, 12 modules in all three lengths, included in every purchase, every employee of the legal entity, 12 months. Pick your company size.
Cheaper as part of a track pack or company library. Delivered within 72 hours of payment or the course is free.
Custom course or custom pricing? A course built on your own procedures and products, a mixed bundle, several legal entities, or a budget that does not fit a table: tell us on WhatsApp and you have a written quote the same day.
Ask about custom courses and custom pricingWho this is for
Roles: Owner, CEO and board, Business development and export sales, Regulatory affairs, Quality assurance and Qualified Person,
Businesses: Finished-dose generic company,
Countries: United States
What you receive
- Audio modules in all three lengths, included in every purchase. The briefing for the board and the sales floor, the standard run for regulatory and quality, the expanded walk-through for the bench. One price buys all three; each person takes the length their role needs. Listen on the commute, at the bench, in the car.
- Made to be listened to. A narrator with character, a story in every module and real examples from the buyer's side of the table. Not a read-out of the guideline that puts the room to sleep.
- Companion workbook. Exercises and checklists per module, ready to file.
- Full transcript. Searchable, printable, quotable in your procedures.
- Source for every fact. Each statement links to its guideline, regulation or paper, so an auditor can check it.
- Certificate per learner. Name, course, hours, guideline version, date.
- Auditable training record. Per-person export for your quality file, the document inspectors ask for under EU GMP Chapter 2.
English first. Other languages are available in test mode on request.
Request a free sample module